Neurocrine Biosciences adopts proxy access bylaw and updates stockholder nomination procedures

NEUROCRINE BIOSCIENCES INC

Proxy access: stockholder(s) holding 3%+ for 3+ years can nominate up to 2 or 20% of directors.
Updated procedural requirements for nominations and proposals, including Rule 14a-19 compliance.
Nominees must provide updated disclosures as of the record date and 5 business days before the meeting.
Nominations disregarded if stockholder fails to comply with Rule 14a-19 or provide timely evidence.
Consent actions require notice to fix record date and use of independent inspectors to validate consents.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

NEUROCRINE BIOSCIENCES INC: Amended and restated Bylaws to implement a proxy access provision and update procedural requirements for stockholder nominations and proposals (effective 2023-02-09).

Change: bylaw amendment
Effective: 2023-02-09

Exact text from the filing

On February 9, 2023, the board of directors (the “Board”) of Neurocrine Biosciences, Inc. (the “Company”) amended and restated the Company’s Bylaws (the “Restated Bylaws”) which became effective immediately upon adoption by the Board.

View on SEC.gov

71 governance changes filed in the last 30 days. Browse all governance changes →

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-23-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.